{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:05:13Z","timestamp":1768896313977,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,10]],"date-time":"2012-10-10T00:00:00Z","timestamp":1349827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Advanced ovarian cancer is characterized by peritoneal metastasis and the accumulation of ascites. Peritoneal metastasis of ovarian cancer is a major cause of the negative treatment outcome, as these metastases are resistant to most chemotherapy regimens. The aim of this study was to clarify aggressive pathology of peritoneal metastasis and examine the therapeutic efficacy of a liposomal agent in the model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A human cancer cell line ES-2 of ovarian clear cell carcinoma, known as a chemotherapy-resistant cancer, was cultured in nonadherent plate to form spheroid and single cell suspension was transplanted into mouse peritoneal cavity. The epidermal growth factor receptor (EGFR) pathways in the cellular aggregates were analyzed both spheroid and ascites. The pharmacokinetics and therapeutic efficacy of CPT-11 (45 mg\/kg) and IHL-305 (45 mg\/kg), an irinotecan-encapsulated liposome, were examined by intravenous administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Established peritoneal metastasis model showed an accumulation of ascites. The activation of EGFR and Akt was demonstrated in cellular aggregates both in the spheroid and ascites. In ascites samples, the area under the curve of SN-38, the activated form of CPT-11, was 3.8 times higher from IHL-305-treated mice than from CPT-11-treated mice. IHL-305 prolonged the survival time and decreased the accumulation of ascites and tumor metastasis. The median survival time were 22, 37 and 54 days in the control, CPT-11-treated, and IHL-305-treated mice, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>EGFR\/Akt pathway contributes to the aggressive progression in ES-2 peritoneal metastasis model and effective delivery into ascites of IHL-305 was thought to useful treatment for ovarian cancer with peritoneal metastasis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-12-462","type":"journal-article","created":{"date-parts":[[2012,10,10]],"date-time":"2012-10-10T16:27:18Z","timestamp":1349886438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse"],"prefix":"10.1186","volume":"12","author":[{"given":"Hiroaki","family":"Konishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimitsu","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norimasa","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,10]]},"reference":[{"key":"3509_CR1","volume-title":"Cancer Facts & Figures 2010","author":"American Cancer Society","year":"2010","unstructured":"American Cancer Society: Cancer Facts & Figures 2010. 2010, Atlanta: American Cancer Society"},{"key":"3509_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/jnci\/djp500","volume":"102","author":"MA Rossing","year":"2010","unstructured":"Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS: Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst. 2010, 102: 222-229. 10.1093\/jnci\/djp500.","journal-title":"J Natl Cancer Inst"},{"key":"3509_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1006\/gyno.2002.6711","volume":"86","author":"CL Trimble","year":"2002","unstructured":"Trimble CL, Kosary C, Trimble EL: Long-term survival and patterns of care in woman with ovarian tumors of low malignant potential. Gynecol Oncol. 2002, 86: 34-37. 10.1006\/gyno.2002.6711.","journal-title":"Gynecol Oncol"},{"key":"3509_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1701-2163(16)30643-0","volume":"26","author":"MF Fung","year":"2004","unstructured":"Fung MF, Bryson P, Johnston M, Charmbers A: Screening postmenopausal women for ovarian cancer: a systematic review. J Obstet Gynaecol Can. 2004, 26: 717-728.","journal-title":"J Obstet Gynaecol Can"},{"key":"3509_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Bunger RA: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006, 354: 34-43. 10.1056\/NEJMoa052985.","journal-title":"N Engl J Med"},{"key":"3509_CR6","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996, 335: 1950-1955. 10.1056\/NEJM199612263352603.","journal-title":"N Engl J Med"},{"key":"3509_CR7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001, 19: 1001-1007.","journal-title":"J Clin Oncol"},{"key":"3509_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1200\/JCO.2006.07.3494","volume":"25","author":"LB Wenzel","year":"2007","unstructured":"Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D: Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2007, 25: 437-443. 10.1200\/JCO.2006.07.3494.","journal-title":"J Clin Oncol"},{"key":"3509_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K, Cassidy J, Manginol C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000, 92: 699-708. 10.1093\/jnci\/92.9.699.","journal-title":"J Natl Cancer Inst"},{"key":"3509_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ijc.23083","volume":"122","author":"H Kajiyama","year":"2008","unstructured":"Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F: Involvement of SDF-1\u03b1\/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer. 2008, 122: 91-99. 10.1002\/ijc.23083.","journal-title":"Int J Cancer"},{"key":"3509_CR11","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1158\/1535-7163.MCT-08-0417","volume":"7","author":"H Yagi","year":"2008","unstructured":"Yagi H, Yotsumoto F, Miyamoto S: Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther. 2008, 7: 3441-3451. 10.1158\/1535-7163.MCT-08-0417.","journal-title":"Mol Cancer Ther"},{"key":"3509_CR12","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1158\/0008-5472.CAN-08-2678","volume":"69","author":"KK Slack-Davis","year":"2009","unstructured":"Slack-Davis KK, Atkins KA, Harrer C, Hershey ED, Conaway M: Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res. 2009, 69: 1469-1476. 10.1158\/0008-5472.CAN-08-2678.","journal-title":"Cancer Res"},{"key":"3509_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/onc.2008.394","volume":"28","author":"M Pickl","year":"2009","unstructured":"Pickl M, Ries CH: Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene. 2009, 28: 461-468. 10.1038\/onc.2008.394.","journal-title":"Oncogene"},{"key":"3509_CR14","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/1078-0432.CCR-08-0905","volume":"15","author":"P Laurent-Puig","year":"2009","unstructured":"Laurent-Puig P, Lievre A, Blons H: Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2009, 15: 1133-1139. 10.1158\/1078-0432.CCR-08-0905.","journal-title":"Clin Cancer Res"},{"key":"3509_CR15","first-page":"1035","volume":"12","author":"A Cabanes","year":"1998","unstructured":"Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A: Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol. 1998, 12: 1035-1040.","journal-title":"Int J Oncol"},{"key":"3509_CR16","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.2001.19.5.1444","volume":"19","author":"G Batist","year":"2001","unstructured":"Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001, 19: 3439-3441.","journal-title":"J Clin Oncol"},{"key":"3509_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/0005-2736(91)90268-D","volume":"1061","author":"TM Allen","year":"1991","unstructured":"Allen TM, Austin GA, Chonn A, Lin L, Lee KC: Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim Biophys Acta. 1991, 1061: 56-64. 10.1016\/0005-2736(91)90268-D.","journal-title":"Biochim Biophys Acta"},{"key":"3509_CR18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.1993.11.5.909","volume":"11","author":"Y Shimada","year":"1993","unstructured":"Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa O: Phase II study of CPT-11, a new Camptothecin derivative, in metastatic colorectal cancer. CPT-11 gastrointestinal cancer study group. J Clin Oncol. 1993, 11: 909-913.","journal-title":"J Clin Oncol"},{"key":"3509_CR19","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1200\/JCO.1992.10.8.1225","volume":"10","author":"N Masuda","year":"1992","unstructured":"Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifiji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M: A new derivative of Camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992, 10: 1225-1229.","journal-title":"J Clin Oncol"},{"key":"3509_CR20","first-page":"189","volume":"27","author":"T Matsuzaki","year":"2012","unstructured":"Matsuzaki T, Takagi A, Furuta T, Ueno S, Kurita A, Nohara G, Kodaira H, Sawada S, Hashimoto S: Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models. Oncol Rep. 2012, 27: 189-197.","journal-title":"Oncol Rep"},{"key":"3509_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jconrel.2009.02.002","volume":"136","author":"H Shmeeda","year":"2009","unstructured":"Shmeeda H, Tzemach D, Mak L, Gabizon A: Her2-targeted pegylated liposomal doxorubicin: Retention of targetspecific binding and cytotoxicity after in vivo passage. J Control Release. 2009, 136: 155-160. 10.1016\/j.jconrel.2009.02.002.","journal-title":"J Control Release"},{"key":"3509_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1089\/cbr.2008.0572","volume":"24","author":"Y-Y Lin","year":"2009","unstructured":"Lin Y-Y, Chang C-H, Lu Y-C, Hwang J-J, Tseng Y-L, Lin W-J, Ting G, Wang H-E: Evaluation of pharmacokinetics of 111In-labeled VNP-PEGylated liposome after intraperitoneal and intravenous administration in a tumor\/ascites mouse model. Cancer Biother Radiopharm. 2009, 24: 453-460. 10.1089\/cbr.2008.0572.","journal-title":"Cancer Biother Radiopharm"},{"key":"3509_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/sj.bjc.6603654","volume":"96","author":"S-S Liau","year":"2007","unstructured":"Liau S-S, Jazag A, Ito K, Whang EE: Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells. British J Cancer. 2007, 96: 993-1000. 10.1038\/sj.bjc.6603654.","journal-title":"British J Cancer"},{"key":"3509_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kugera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996, 334: 1-6. 10.1056\/NEJM199601043340101.","journal-title":"N Engl J Med"},{"key":"3509_CR25","first-page":"45","volume":"27","author":"A Takagi","year":"2007","unstructured":"Takagi A, Watanabe M, Ishii Y, Morita J, Hirokawa Y, Matsuzaki T, Shiraishi T: Three-dimensional cellular spheroid formation provides human prostate tumor cell with tissue-like features. Anticancer Res. 2007, 27: 45-54.","journal-title":"Anticancer Res"},{"key":"3509_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00280-009-1132-4","volume":"66","author":"A Gabizon","year":"2009","unstructured":"Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S: Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol. 2009, 66: 43-52.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3509_CR27","doi-asserted-by":"publisher","first-page":"e1279","DOI":"10.1371\/journal.pone.0001279","volume":"2","author":"AL Estep","year":"2007","unstructured":"Estep AL, Palmer C, McComick F, Rauen KA: Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One. 2007, 2: e1279-10.1371\/journal.pone.0001279.","journal-title":"PLoS One"},{"key":"3509_CR28","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1158\/0008-5472.CAN-04-0304","volume":"64","author":"A Sako","year":"2004","unstructured":"Sako A, Kitayama J, Koyama H, Ueno H, Uchida K, Hamada H, Nagawa H: Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res. 2004, 64: 3624-3628. 10.1158\/0008-5472.CAN-04-0304.","journal-title":"Cancer Res"},{"key":"3509_CR29","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","volume":"88","author":"T Sugiyama","year":"2000","unstructured":"Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary. Cancer. 2000, 88: 2584-9. 10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5.","journal-title":"Cancer"},{"key":"3509_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/jps.2600570301","volume":"57","author":"BE Ballard","year":"1968","unstructured":"Ballard BE: Biopharmaceutical considerations in subcutaneous and intramuscular drug administration. J Pharm Sci. 1968, 57: 357-378. 10.1002\/jps.2600570301.","journal-title":"J Pharm Sci"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-462.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-462\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-462.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:30:04Z","timestamp":1630614604000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,10]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3509"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-462","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,10]]},"assertion":[{"value":"30 March 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"462"}}